🏛️ Verified NIH Record • Updated 2026-07-15
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases (NCT05704647)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: M.D. Anderson Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Who can join: Review the eligibility criteria below.
Location: M D Anderson Cancer Center — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- M D Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (713) 792-4185
Email: htawbi@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma (Skin)
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma — Birmingham, Alabama
- Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma — Tampa, Florida
- A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma — Toronto, Ontario
- Zr89 + PET Companion Trial — Philadelphia, Pennsylvania
- Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma — Orange, California
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors — La Jolla, California
Explore by condition: All Melanoma (Skin) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.